Hematopoiesis News Volume 13.46 | Nov 22 2022

    By
    Noshin Noorjahan
    -
    0
    23








    2022-11-22 | HN 13.46


    Hematopoiesis News by STEMCELL Technologies
    Vol. 13.46 – 22 November, 2022
    TOP STORY

    Aging Drives Tet2+/- Clonal Hematopoiesis via IL-1 Signaling

    Using bone marrow (BM) transplantation and newly developed genetic mosaicism mouse models of Tet2+/--driven clonal hematopoiesis of indeterminate potential, scientists observed an association between increased Tet2+/- clonal expansion and higher BM levels of the inflammatory cytokine IL-1 upon aging.
    [Blood]

    Abstract
    Cell Preparation For Crossmatch Assays
    PUBLICATIONSRanked by the impact factor of the journal

    Regulome Analysis in B-Acute Lymphoblastic Leukemia Exposes Core Binding Factor Addiction as a Therapeutic Vulnerability

    Researchers characterized the ETS translocation variant 6-runt-related transcription factor 1 regulome by integrating chromatin immunoprecipitation- and RNA-sequencing.
    [Nature Communications]

    Full Article

    Isocitrate Dehydrogenase 1 Mutation Drives Leukemogenesis by PDGFRA Activation Due to Insulator Disruption in Acute Myeloid Leukemia (AML)

    Using public RNA-Seq data, investigators identified upregulation of tyrosine kinase PDGFRA in IDH1-mutant patients, correlating with poor prognosis.
    [Leukemia]

    Full ArticleGraphical Abstract

    Intracellular Angiopoietin-1 Promotes TKI-Resistance via Activation of JAK/STAT5 Pathway in Chronic Myeloid Leukemia

    The authors investigated the role of angiopoietin-1 as a potential prognostic factor for drug resistance in chronic myeloid leukemia.
    [Oncogene]

    Abstract

    An ATP-Binding Cassette Transporter G2 (CgABCG2) Regulates the Haemocyte Proliferation by Modulating the G1/S Phase Transition of Cell Cycle in Oyster Crassostrea gigas

    A homologue of ABCG2, named as CgABCG2, with the conserved AAA domain and ABC2 membrane domain was identified from the Pacific oyster Crassostrea gigas.
    [Fish & Shellfish Immunology]

    Full Article

    The RNA Editing Landscape in Acute Myeloid Leukemia Reveals Associations with Disease Mutations and Clinical Outcome

    Using high throughput transcriptomic data from The Cancer Genome Atlas, scientists demonstrated higher levels of RNA editing as a predictor of poor outcome within the acute myeloid leukemia patient samples.
    [iScience]

    AbstractGraphical Abstract

    Targeting Arginase-1 Exerts Antitumor Effects in Multiple Myeloma and Mitigates Bortezomib-Induced Cardiotoxicity

    The authors investigated the role of arginase 1 (ARG1) in Vκ*MYC model of multiple myeloma in mice. ARG1 expression in myeloid cells correlated with tumor progression and was accompanied by a systemic drop in ʟ-arginine levels.
    [Scientific Reports]

    Full Article

    Effects of hsa-miR-9-3p and hsa-miR-9-5p on Topoisomerase IIβ Expression in Human Leukemia K562 Cells with Acquired Resistance to Etoposide

    Using microRNA (miRNA) sequencing and quantitative PCR, researchers found that both miR-9-3p and miR-9-5p were overexpressed in the etoposide-resistant K562 clonal subline, K/VP.5 compared with K562 cells.
    [Journal of Pharmacology and Experimental Therapeutics]

    AbstractFull Article

    An Effective and Chemotherapy-Free Strategy of All-Trans Retinoic Acid and Arsenic Trioxide for Acute Promyelocytic Leukemia in All Risk Groups (APL15 Trial)

    Investigators performed a randomized multi-center non-inferiority Phase III study to compare the efficacy of all-trans retinoic acid (ATRA)-arsenic trioxide (ATO) and ATRA-ATO plus chemotherapy in newly diagnosed all-risk acute promyelocytic leukemia patients.
    [Blood Cancer Journal]

    Full Article

    FLT3 Inhibitors as Maintenance Therapy Post Allogeneic Hematopoietic Stem Cell Transplantation in Acute Myeloid Leukemia Patients with FLT3 Mutations: A Meta-Analysis

    The authors compared overall survival, relapse-free survival, cumulative incidence of relapse, non-relapse mortality, graft-versus-host disease, and adverse events between FLT3 inhibitors and control groups.
    [Cancer Medicine]

    Full Article

    Peripheral Blood Mononuclear Cell Phenotype and Function Are Maintained after Overnight Shipping of Whole Blood

    Whole blood was collected from healthy control subjects and processed fresh or at 6, 24, and 48 h after collection and handling under modeled shipping conditions.
    [Scientific Reports]

    Full Article

    SLIT2 Promoter Hypermethylation Predicts Disease Progression in Chronic Myeloid Leukemia

    The level of slit guidance ligand 2 (SLIT2) promoter methylation was determined in 104 chronic myeloid leukemia patients, and its clinical significance was analyzed.
    [European Journal of Medical Research]

    Full Article
    ON903-COVID-19 Digital Resources 728 x 90
    REVIEWS

    Myelodysplastic Syndromes

    The authors review the current understanding of myelodysplastic syndrome biology to determine the prospect of new therapeutic approaches.
    [Nature Reviews Disease Primers]

    Abstract
    INDUSTRY AND POLICY NEWS

    Phase III Trial of ICLUSIG® (Ponatinib) Met Primary Endpoint in Newly-Diagnosed Ph+ ALL, a Setting with No Targeted Treatments Approved in the US

    Takeda announced that their Phase III trial met its primary endpoint, demonstrating that adult patients with newly-diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia treated with ICLUSIG® plus chemotherapy achieved higher rates of remission compared to imatinib.
    [Takeda]

    Press Release
    FEATURED EVENT

    ESMO Targeted Anticancer Therapies Congress 2023

    March 6 – 8, 2023
    Paris, France

    > See All Events

    JOB OPPORTUNITIES

    Postdoctoral Research Fellow – Chronic Lymphocytic Leukemia Center

    Dana-Farber Cancer Institute – Boston, Massachusetts, United States

    Postdoctoral Position – Transcription in Hematopoiesis and Leukemia

    University of Pennsylvania – Philadelphia, Pennsylvania, United States

    Scientist – Hematological Cancers, Oncology Bioscience

    AstraZeneca – Waltham, Massachusetts, United States

    Faculty Position – Division of Hematology

    Washington University School of Medicine – St. Louis, Missouri, United States

    Co-Director – Pediatric Hematologic Malignancy Program

    Johns Hopkins School of Medicine – Baltimore, Maryland, United States

    > See All Jobs

    Submit an article, publication, job or event
    Brought to you by
    stemcell-logo-for newsletter-2
    Hematopoiesis News Twitter